Abstract:Protein arginine methyltransferase 1 (PRMT1), which primarily causes asymmetric arginine methylation of histone and nonhistone proteins, has been found to activate gene expression and mediate multiple pathological processes. Its role in renal fibrosis, however, remains unclear. In the present study, we observed that PRMT1 and its specific epigenetic marker, asymmetric di-methylated histone 4 arginine 3 (H4R3Me2a), were highly expressed in cultured renal interstitial fibroblasts. Treatment of PRMT1 with AMI-1, a selective inhibitor of PRMT1, or silencing PRMT1 with siRNA inhibited serum-induced and transforming growth factor (TGF)-beta(1)-induced expression of alpha-smooth muscle actin (alpha-SMA) and collagen type I, two hallmarks of renal fibroblast activation, in a dose-dependent and time-dependent manner. In a murine model of renal fibrosis induced by unilateral ureteral obstruction, PRMT1 expression and H4R3Me2a were also upregulated, which was coincident with increased expression of alpha-SMA, collagen type I, and fibronectin. Administration of AMI-1 reduced PRMTI and II4R3Me2a expression. attenuated extracellular matrix protein deposition, and inhibited renal fibroblast activation and proliferation. Moreover, AMI-1 treatment inhibited Smad3 phosphorylation and TGF-beta receptor I expression but prevented Smad7 downregulation both in the kidney after unilateral ureteral obstruction injury and in cultured renal interstitial fibroblasts exposed to TGF-beta(1). Collectively, these results demonstrate that PRMT1 may mediate renal fibroblast activation and renal fibrosis development through activation of the TGF-beta/Smad3 signaling pathway. They also suggest that PRMT1 inhibition may be a potential therapeutic approach for the treatment of fibrotic kidney disease.

Protein arginine methyltransferases in renal development, injury, repair, and fibrosis.

The Role Of Protein Arginine Methyltransferases In Kidney Diseases

Protein arginine methylation of non-histone proteins and its role in diseases.

Protein Arginine Methyltransferases (PRMTs): Orchestrators of Cancer Pathogenesis, Immunotherapy Dynamics, and Drug Resistance

Protein arginine methylation: from enigmatic functions to therapeutic targeting

Protein Arginine Methyltransferase 1 is Required for Maintenance of Normal Adult Hematopoiesis

PRMT1 in human neoplasm: cancer biology and potential therapeutic target

The Role of PRMT1 in Cellular Regulation and Disease: Insights into Biochemical Functions and Emerging Inhibitors for Cancer Therapy

Protein Arginine Methyltransferases in Cardiovascular and Neuronal Function

Protein arginine methyltransferase 1 mediates renal fibroblast activation and fibrogenesis through activation of Smad3 signaling

The role of protein arginine N-methyltransferases in inflammation

The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond

Overview of PRMT1 modulators: Inhibitors and degraders

Structure, Function, and Activity of Small Molecule and Peptide Inhibitors of Protein Arginine Methyltransferase 1

Protein arginine methyltransferases: promising targets for cancer therapy

Research progress on PRMTs involved in epigenetic modification and tumour signalling pathway regulation (Review)

The regulation, functions and clinical relevance of arginine methylation

The Role and Mechanism of Lysine Methyltransferase and Arginine Methyltransferase in Kidney Diseases

The Structure and Functions of PRMT5 in Human Diseases

Small Molecule Inhibitors of Protein Arginine Methyltransferases

Correlation of protein arginine methyltransferase with the occurrence and development of malignancy